Humira to Assume Lipitor’s Crown as Pfizer Feels the Heat From Sanofi and Novartis
LONDON, June 28, 2011 /PRNewswire/ –
Rheumatoid arthritis treatment Humira will assume Lipitor’s crown as the
world’s biggest selling drug, while Pfizer will cling on to its ranking as
the biggest seller of prescription medicines through to 2016, according to
the World Preview 2016 (second edition) report published today by
EvaluatePharma, the premier provider of pharma and biotech analysis.
Lipitor’s patent expiry this year precipitates the steepest decline in
the industry’s patent cliff, with $139bn predicted to be lost from sales of
branded drugs between 2011 and 2016, equal to 20% of the global
pharmaceutical market last year. Meanwhile the race for the pharmaceutical
sales top spot is going to be close, with Sanofi and Novartis breathing down
Pfizer’s neck – all three companies are expected to have prescription drug
sales in the region of $50bn by 2016, the EvaluatePharma report shows.
Despite predictions that sales of its prescription drugs are set to
decline from $54.1bn last year to $51.2bn by 2016, Pfizer is expected to
just cling on to the industry’s top spot – but Sanofi and Novartis are
catching up fast.
Sanofi’s $20bn acquisition of Genzyme, predicted growth in emerging
markets and its vaccines business have significantly boosted the outlook for
the French group’s pharmaceutical revenues – forecast sales in 2016 of
$50.2bn are $11.2bn higher than in the same analysis conducted in April
Prospects for Novartis’ pharmaceutical business have been boosted by key
regulatory approvals for oral MS pill Gilenya and Tasigna, a follow-on
product to leukaemia blockbuster Glivec.
Change in WW Market WW Prescription (Rx) WW Annual Sales 2016 vs. Market Rank Sales ($bn) Apr-2010 Share (10-16) Growth Rank Company 2010 2016 (10-16) 2010 2016 1 Pfizer 54.1 51.2 -1% +4.0 8.0% 6.0% - 2 Sanofi 36.6 50.2 +5% +11.2 5.4% 5.9% +2 3 Novartis 41.4 49.7 +3% +2.6 6.1% 5.8% -1 4 GlaxoSmithKline 35.6 45.0 +4% +6.3 5.3% 5.3% +2 -0.3 5 Roche 35.6 43.6 +3% 5.3% 5.1% - -4.0 6 Merck & Co 40.4 42.3 +1% 6.0% 5.0% -3 7 AstraZeneca 32.1 27.0 -3% +4.9 4.7% 3.2% - -1.7 8 Abbott Laboratories 19.9 24.4 +3% 2.9% 2.9% +2 9 Teva Pharmaceutical 14.5 23.9 +9% +3.1 2.1% 2.8% +4 -2.9 10 Johnson & Johnson 20.7 21.9 +1% 3.1% 2.6% -1
Once again the fastest growing company in the top ten in terms of
prescription revenues is expected to be Israeli company Teva. The generics
firm is rapidly becoming a big pharma player through an aggressive M&A
strategy which increasingly spans the industry spectrum from generics to
innovative technologies. The EvaluatePharma report shows that Teva increased
its share of the global generics market to 18% in 2010 and the company is
well placed to benefit the most from the blockbuster patent cliff.
In contrast, the outlook for Merck & Co has been tempered somewhat, hit
hardest by the phase III failure of novel anti-coagulant, vorapaxar. A year
ago Merck was seen as Pfizer’s closest rival for the top spot in 2016, but
the company now sits outside the top five.
Humira reigns supreme
Estimated global sales of Lipitor of $10.6bn means 2011 will be the last
year the cholesterol-lowering agent tops the rankings, with Humira expected
to be the biggest selling medicine in 2012 with sales of $8.7bn. Humira is
forecast to grow 5% annually to reach $9.7bn by 2016, almost $2bn higher
than its nearest challenger, Roche’s Avastin. The cancer antibody was once
regarded as Lipitor’s heir apparent before a number of clinical and
regulatory setbacks in the last 18 months.
Biotech products targeting cancer and rheumatic disorders are seen
accounting for six of the top ten products in 2016. Of the three small
molecule drugs, AstraZeneca’s cholesterol drug Crestor has been boosted by a
successful legal defence of its patent until 2016. A receding generic threat
in the US is benefitting Glaxo’s respiratory medicine Advair, while Merck &
Co’s Januvia franchise goes from strength to strength and is expected to
dominate the non-insulin market for diabetes agents.
2016 WW Product Change vs Top Ten Selling Products in 2016 Sales ($bn) Apr-10 % Rank Product Company(s) Target Technology 2010 2016 Growth Biotech Abbott + (monoclonal 1 Humira Eisai Arthritis antibody) 6.7 9.7 +5% -405 -4% Biotech (monoclonal 2 Avastin Roche Cancer antibody) 6.2 7.8 +3% -1078 -12% Biotech Roche + (monoclonal 3 Rituxan Biogen Idec Cancer antibody) 6.1 7.7 +3% +897 +13% AstraZeneca Conventional + Shionogi (small 4 Crestor + Chiesi Cholest- molecule) 6.1 7.5 +3% +1242 +20% Amgen + erol Biotech Pfizer + (recombinant 5 Enbrel Takeda Arthritis product) 7.3 7.2 -0% -119 -2% GSK + Conventional Seretide Almirall + Asthma / (small 6 / Advair Faes COPD molecule) 8.1 7.0 -2% +1768 +34% Conventional Januvia /Merck + Ono (small 7 Janumet + Almirall Diabetes molecule) 3.5 6.8 +10% +791 +13% Biotech (monoclonal 8 HerceptinRoche Cancer antibody) 5.2 6.5 +3% +300 +5% J&J + Merck + Biotech Mitsubishi (monoclonal 9 Remicade Tanabe Arthritis antibody) 6.5 6.1 -1% +380 +7% Biotech Prevnar Pneumoc- (bioengineered 10 13 Pfizer occal vaccine) 2.4 5.8 +13% +4081 +237% diseas
Commenting on the launch of the report, Jonathan de Pass, founder and
chief executive of EvaluatePharma, said: “Our revised outlook for 2016 shows
how competitive the landscape will be for the big pharma players – key
pipeline successes or failures, or the outcome of courtroom patent battles,
could dramatically change the current picture”.
“Our World Preview report provides valuable insight into life beyond the
patent cliff and who the likely winners and losers will be”.
EvaluatePharma launched the report today at BIO 2011 in Washington DC,
More information on EvaluatePharma’s World Preview 2016, which assesses
forecasted trends in prescription drug sales, R&D spend, therapy area growth
and the performance of marketed and pipeline products, can be found at
EvaluatePharma’s stand at BIO 2011 (3045) or via EvaluatePharma’s website
About EvaluatePharma (R) – http://www.evaluatepharma.com
Set up in 1996 by former top pharma analyst Dr. Jonathan de Pass,
EvaluatePharma(R) is the premier source for pharma and biotech analysis.
EvaluatePharma was the first company to supply reliable consensus
forecasts of global drug sales and now provides standardised worldwide
financial and forecast models with consensus product forecasts to 2016, data
on R&D pipelines, licensing deals, patent risk and M&A deals, along with
analytical tools that include, Merge Company and Peer Group Analyzer and
over 3000 global product NPVs (Net Present Value) linked to share price.
In 2007 EvaluatePharma(R)Alpha launched offering a valuation service
designed to quantify market events and the impact on product, portfolio and
company valuation – NPV Analyzer, Calendar of Events and the daily news
service EP Vantage.
For all media enquiries please contact: Andrew Beaven Marketing Director, EvaluatePharma Ltd T: +44(0)20-7539-1818 E: email@example.com EvaluatePharma Ltd 11-29 Fashion Street London E1 6PX United Kingdom
SOURCE EvaluatePharma Ltd